The Knowledge People with Learning Disabilities and their Carers have about Psychotropic Medication

Tizard Learning Disability Review

Volumn 10, Issue 4, 2005, Pages 10-18

  Heslop, Pauline ^a   Folkes, Liz ^a   Rodgers, Jackie ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84993029980     PISSN: 13595474     EISSN: None     Source Type: Journal    
DOI: 10.1108/13595474200500033     Document Type: Review

References (16)

1. Arscott K, Stenfert Kroese B & Dagnan D. (2000) A study of the knowledge that people with intellectual disabilities have of their prescribed medication. Journal of Applied Research in Intellectual Disabilities 13 (2) 90-9.
2. Ashcroft R, Fraser B, Kerr M & Ahmed Z. (2001) Are antipsychotic drugs the right treatment for challenging behaviour in learning disability? The place of a randomised trial. Journal of Medical Ethics 27 338-43.
3. Bramble D. (2003) Annotation: the use of psychotropic medications in children: a British view. Journal of Child Psychology and Psychiatry 44 (2) 169-79.
4. Briggs R. (1989) Monitoring and evaluating psychotropic drug use for persons with mental retardation: a follow-up report. American Journal of Mental Retardation 93 633-9.
5. Christian L, Snycerski SM, Singh NN & Poling A. (1999) Direct service staff and their perceptions of psychotropic medication in non-institutional settings for people with intellectual disability. Journal of Intellectual Disability Research 43 (2) 88-93.
6. Department of Health (2003) Care Homes for Adults (18-65) and Supplementary Standards for Care Homes Accommodating Young People aged 16 and 17: National minimum standards care homes regulations. London:The Stationery Office.
7. Glaser B & Strauss A. (1967) The Discovery of Grounded Theory. Chicago: Aldine.
8. Lindsey M. (1998) Signposts for Success in Commissioning and Providing Health Services for People with Learning Disabilities. London: NHS Executive.
9. Nursing and Midwifery Council (2002) Guidelines for the Administration of Medicines. London: Nursing and Midwifery Council.
10. Poindexter AR. (1989) Psychotropic drug patterns in a large ICF/MR facility. A ten-year experience. American Journal of Mental Retardation 93 624-6.
11. Reiss S & Aman MG. (1998) The international consensus process on psychopharmacology and intellectual disability. Journal of Intellectual Disability Research 41 (6) 448-55.
12. Robertson J, Emerson E, Gregory N et al (2000) Receipt of psychotropic medication by people with learning disability in residential settings. Journal of Intellectual Disability Research 44 (6) 666-76.
13. Singh NN, Ellis CR, Donatelli LS et al (1996) Professionals’ perceptions of psychotropic medication in residential facilities for individuals with mental retardation. Journal of Intellectual Disability Research 40 (1) 1-7.
14. Strydom A, Forster M, Wilkie BM, Edwards C & Hall IS. (2001) Patient information leaflets for people with learning disabilities who take psychiatric medication. British Journal of Learning Disabilities 29 72-6.
15. VERBI. (2001) MAXqda Qualitative Data Analysis. Berlin: VERBI software.
16. Wilson JG, Lott RS & Tsai L. (1998) Side effects: recognition and management. In: A Reiss & MG Aman (Eds) Psychotropic Medications and Developmental Disabilities:The International Consensus Handbook. Columbus, OH: The Ohio State University Press.